98%
921
2 minutes
20
Affective and non-affective psychotic disorders are associated with variable levels of impairment in affective processing, but this domain typically has been examined via presentation of static facial images. We compared performance on a dynamic facial expression identification task across six emotions (sad, fear, surprise, disgust, anger, happy) in individuals with psychotic disorders (bipolar with psychotic features [PBD] = 113, schizoaffective [SAD] = 163, schizophrenia [SZ] = 181) and healthy controls (HC; n = 236) derived from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). These same individuals with psychotic disorders were also grouped by B-SNIP-derived Biotype (Biotype 1 [B1] = 115, Biotype 2 [B2] = 132, Biotype 3 [B3] = 158), derived from a cluster analysis applied to a large biomarker panel that did not include the current data. Irrespective of the depicted emotion, groups differed in accuracy of emotion identification (P < 0.0001). The SZ group demonstrated lower accuracy versus HC and PBD groups; the SAD group was less accurate than the HC group (Ps < 0.02). Similar overall group differences were evident in speed of identifying emotional expressions. Controlling for general cognitive ability did not eliminate most group differences on accuracy but eliminated almost all group differences on reaction time for emotion identification. Results from the Biotype groups indicated that B1 and B2 had more severe deficits in emotion recognition than HC and B3, meanwhile B3 did not show significant deficits. In sum, this characterization of facial emotion recognition deficits adds to our emerging understanding of social/emotional deficits across the psychosis spectrum.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236198 | PMC |
http://dx.doi.org/10.1016/j.schres.2021.11.027 | DOI Listing |
Tidsskr Nor Laegeforen
September 2025
Avdeling for blodsjukdomar, St. Olavs hospital.
Background: Abnormal blood test results are common in both primary and specialist health care. The cause is often multifactorial, and investigations are often conducted across various specialties. We present a patient with incidental disturbances in the blood count with a serious causal relationship.
View Article and Find Full Text PDFBr J Psychiatry
September 2025
City St George's, University of London, London, UK.
Neuropsychiatr Dis Treat
August 2025
Geriatric Medicine Department II, Qingdao Mental Health Center, Qingdao, Shandong, People's Republic of China.
Purpose: Previous studies have shown that serum uric acid (UA) levels are significantly higher in patients with bipolar disorder (BD) than in patients with depressive disorder (DD), schizophrenia, and healthy controls. Currently, studies generally report that there is a complex bidirectional interaction between mood disorders (MD) and hyperuricemia (HUA). We investigated the prevalence and related factors of hyperuricemia in Chinese patients with mood disorders to find out potential mechanisms and build a predictive model.
View Article and Find Full Text PDFIntegr Med Res
March 2026
KM Science Research Division, Korea Institute of Oriental Medicine, South Korea.
Background: Depression is a common comorbidity of schizophrenia spectrum disorder (SSDs) that affects functional outcomes and quality of life. This systematic review and meta-analysis evaluated the effectiveness of herbal medicine as an adjunct therapy to antipsychotics in patients with SSDs and comorbid depression.
Methods: Eight databases were searched from inception to January 2025 for randomized controlled trials (RCTs) evaluating herbal medicine combined with antipsychotics vs antipsychotics alone in patients with SSDs and comorbid depression.
Biol Psychiatry Glob Open Sci
November 2025
Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
Background: Neuroimmune processes are often implicated in young people with atypical neuropsychiatric disorders, yet treatment implications remain controversial. This case series details young people with primary psychiatric disorders who received adjunctive immunotherapy after thorough investigation and extensive conventional treatments.
Methods: We evaluated 45 individuals (93% female, ages 12-30 years) with atypical psychiatric presentations suggesting potential neuroimmune involvement.